Sejal Desai
Family Medicine · Katy, TXNPI 1932362829
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $9,750 of the $14,379 with a category attached, or 67.8%. Rhythm Pharmaceuticals, Inc. accounts for 70.9% of it on its own, with 32 other manufacturers making up the rest. Reporting peaked in 2021 at $7,563 and has fallen 92.7% since, to $554 in 2025. Among family medicine clinicians in TX with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 247 payments — averaging $58.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rhythm Pharmaceuticals, Inc.$10K
- Novo Nordisk$935
- Lilly USA, LLC$364
- Abbott$347
- Dexcom, Inc.$244
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$209
- plus $2K from 27 others
What the payments were for
- Speaking & faculty fees$9,75068%
- Travel & lodging$771%
- Food & beverage$4,52131%
- Education$310%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rhythm Pharmaceuticals, Inc. | 13 | $10,199 |
| Novo Nordisk | 39 | $935 |
| Lilly USA, LLC | 31 | $364 |
| Abbott | 17 | $347 |
| Dexcom, Inc. | 7 | $244 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 14 | $209 |
| AbbVie(2 entities) | 13 | $198 |
| Amarin Pharma, Inc. | 12 | $193 |
| Pfizer | 13 | $184 |
| Amgen | 11 | $173 |
| Merck | 15 | $161 |
| Boehringer Ingelheim | 10 | $158 |
| AstraZeneca | 9 | $137 |
| Eisai Inc. | 7 | $123 |
| Kvk-tech, Inc. | 2 | $117 |
| Medtronic | 1 | $86 |
| Johnson & Johnson | 5 | $82 |
| Sanofi-aventis U.S. LLC | 4 | $60 |
| Novartis | 3 | $55 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $48 |
| Optinose US, Inc. | 3 | $39 |
| Kowa Pharmaceuticals America, Inc. | 3 | $38 |
| Genentech USA, Inc. | 2 | $34 |
| GSK | 2 | $33 |
| Myocardial Solutions, Inc. | 1 | $28 |
| Mylan Specialty L.p. | 1 | $21 |
| Corcept Therapeutics | 1 | $21 |
| Currax Pharmaceuticals LLC | 1 | $17 |
| Philips North America LLC | 1 | $16 |
| Shire North American Group Inc | 1 | $16 |
| Antares Pharma, Inc. | 1 | $16 |
| Biohaven Pharmaceutical Holding Company Ltd. | 1 | $15 |
| Irhythm Technologies, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Imcivree$3,424
- Wegovy$125
- DEXCOM G7 GSS (161)$118
- DEXCOM STELO GLUCOSE BIOSENSOR$118
How this compares
$14,379 in reported general payments places this provider in the 95th percentile of 8,760 family medicine providers in Texas.
Other family medicine in Katy
- Carlos CamposNew Braunfels$1.5M
- Aaron KingSan Antonio$1.1M
- Bradley WassonArlington$734K
- Cynthia BrinsonAustin$402K
- Michael MendezLubbock$368K
- Sang Tae KimAmarillo$368K
- Sumit PerakathuHarlingen$342K
- Joel SolisMcAllen$324K
- Robert CampbellFort Worth$318K
- Jose LedezmaEdinburg$300K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.